In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the \u201coperation summary\u201d below, containing the information provided by the parties.<\/p>\n
This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation.<\/p>\n
The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented.<\/p>\n
Names of the companies and groups concerned:<\/strong><\/p>\n Nature of the operation<\/strong><\/p>\n Economic sectors concerned<\/strong><\/p>\n Deadline for interested third parties to submit their observations<\/strong><\/p>\n NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES<\/strong><\/p>\n The Competition Council has received notification of an economic concentration operation concerning the acquisition of exclusive control of the company \u201cOpella Healthcare SAS\u201d by the company \u201cClayton, Dubilier & Rice Fund XII, LP\u201d through the acquisition of approximately 50% of its capital and associated voting rights.<\/p>\n \u201cClayton, Dubilier & Rice Fund XII, LP\u201d is a private equity fund registered in the Cayman Islands and controlled by \u201cClayton, Dubilier & Rice\u201d, a private investment group based in the United States. The group’s strategy is to acquire and manage stakes in companies across various sectors, including industry, business services, financial services, distribution, healthcare, and technology.<\/p>\n \u201cOpella Healthcare SAS\u201d is a French simplified joint-stock company. The company is a subsidiary of the Sanofi group and is primarily active globally in the research, development, manufacturing, and marketing of over-the-counter pharmaceutical products, vitamins, minerals, dietary supplements, cosmetics, and other personal care products.<\/p>\n <\/p>\n Done in Rabat on December 12, 2024<\/p>\n","protected":false},"excerpt":{"rendered":" In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the \u201coperation summary\u201d below, containing the information provided by the parties. This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation. The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented. Names of the companies and groups concerned: The acquirer: \u201cClayton, Dubilier & Rice Fund XII, LP\u201d; The target: \u201cOpella Healthcare SAS\u201d; Nature of the operation Acquisition of exclusive control. Economic sectors concerned Pharmaceuticals and dietary supplements sector. Deadline for interested third parties to submit their observations 10 days from the date of publication of this press release, i.e. December 26, 2024. NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES The Competition Council has received notification of an economic concentration operation concerning the acquisition of exclusive control of the company \u201cOpella Healthcare SAS\u201d by the company \u201cClayton, Dubilier & Rice Fund XII, LP\u201d through the acquisition of approximately 50% of its capital and associated voting rights. \u201cClayton, Dubilier & Rice Fund XII, LP\u201d is a private equity fund registered in the Cayman Islands and controlled by \u201cClayton, Dubilier & Rice\u201d, a private investment group based in the United States. The group’s strategy is to acquire and manage stakes in companies across various sectors, including industry, business services, financial services, distribution, healthcare, and technology. \u201cOpella Healthcare SAS\u201d is a French simplified joint-stock company. The company is a subsidiary of the Sanofi group and is primarily active globally in the research, development, manufacturing, and marketing of over-the-counter pharmaceutical products, vitamins, minerals, dietary supplements, cosmetics, and other personal care products. Done in Rabat on December 12, 2024<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[352],"tags":[],"class_list":["post-40237","post","type-post","status-publish","format-standard","hentry","category-press-releases"],"acf":[],"yoast_head":"\n\n
\n
\n
\n